Loading...
On December 19, 2014, the FDA announced the approval of ceftolozane/tazobactam (Zerbaxa) for treatment of adults with complicated urinary tract infections (cUTIs) and complicated intra-abdominal infections (cIAIs) caused by susceptible organisms. In trials among hospitalized adults, the drug was noninferior to intravenous levofloxacin for the former indication and, when combined with metronidazole, noninferior to meropenem for the latter. Ceftolozane/tazobactam is the fourth new drug in 2014 to be designated as a Qualified Infectious Disease Product under the new Generating Antibiotic Incentives Now title of the FDA Safety and Innovation Act.
Compared with currently available cephalosporins, ceftolozane/tazobactam has improved activity again…